查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654139

美國醫藥第三方物流服務市場規模、佔有率、趨勢分析報告：按產品類型、溫度、治療領域、製造商規模、服務、細分預測，2025-2030 年

U.S. Pharmaceutical Third-party Logistics Services Market Size, Share & Trends Analysis Report By Product Type, By Temperature, By Therapeutic Area, By Manufacturer Size, By Service, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國醫藥第三方物流服務市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，美國醫藥第三方物流（3PL）服務市場規模預計到2030年將達到754.1億美元，2025年至2030年期間的複合年成長率為8.90%。

市場對高效、安全的供應鏈解決方案的需求不斷成長、藥品分銷的複雜性日益增加以及遵守嚴格的監管標準的需要不斷推動。此外，對生技藥品和疫苗等溫度敏感型特種藥品的需求不斷成長，推動了低溫運輸物流的重要性，製藥公司轉向第三方物流供應商尋求先進的儲存和運輸解決方案。

此外，先進技術的發展提高了醫藥物流的效率和安全性，也促進了市場的成長。隨著醫療物流業務變得越來越複雜，越來越依賴自動資料報告系統來簡化合規性和效能監控。自動彙報解決方案可協助醫藥第三方物流供應商產生關鍵績效指標 (KPI)（例如準時交貨率、產品狀況和法規遵循）的即時、準確的報告。這些系統還可以自動產生監管機構所需的報告，減少手動工作並確保所有必需的文件按時提交。

此外，對溫度敏感的藥品和生物製藥的需求不斷成長，大大刺激了低溫運輸物流市場的擴張。隨著對這些敏感產品的安全儲存和運輸的需求不斷成長，主要企業正在轉向創新的低溫運輸解決方案來保障產品品質和效力。此外，隨著人工智慧的融入，科技不斷進步，進一步推動了醫藥產業對低溫運輸物流的需求。根據《Pharmaceutical Commerce》在2024年10月發表的報導，人工智慧（AI）有可能透過多種變革性的方式改變透過低溫運輸運輸的溫度敏感藥品的物流。人工智慧可以透過預測分析、即時監控以及路線和資源最佳化使供應鏈更加高效和可靠。

市場的主要企業包括 Cencora Corporation、Kuehne+Nagel、Kerry Logistics Network Limited、Cardinal Health、McKesson Corporation 和 Thermo Fisher Scientific。市場參與者正在採取關鍵策略舉措來增強其市場影響力並擴大業務。例如，2023 年 4 月，Kuehne+Nagel 宣布將在達拉斯-沃斯堡國際機場附近建造一個佔地 40 萬平方英尺的合約物流履約中心。該設施距離航站樓三英里，彰顯了該公司在醫療物流的戰略投資，旨在為多個客戶提供尖端服務。

美國醫藥第三方物流服務市場報告重點

  • 根據產品，由於糖尿病、高血壓和心血管疾病等慢性疾病的增加，品牌藥品領域預計將在 2024 年佔據市場主導地位。這些疾病的日益普及導致美國對品牌藥物的需求增加。
  • 依溫度分類，2024 年常溫佔最大銷售佔有率。對於不需要冷藏或冷凍的產品（例如某些口服藥物和非處方藥物），常溫儲存至關重要。
  • 根據治療領域，腫瘤學在 2024 年佔據最大的收入佔有率。隨著全國癌症患者數量的增加，該領域的市場可能會擴大。此外，最近的趨勢是癌症治療取得了重大進展，人們對藥物的關注度日益提高。
  • 根據製造商規模，大型製造商將在 2024 年佔據最大的銷售佔有率。大型製造商擁有豐富的資源和成熟的供應鏈。這些公司通常擁有龐大的生產能力和廣泛的產品系列，這使得他們能夠與物流供應商協商出有利的條款。
  • 按服務分類，倉儲和運輸在 2024 年佔據了最大的收入佔有率。隨著競爭格局加劇和流程變得更加複雜，製藥公司不斷尋找新方法來最佳化供應鏈生產力並遵守行業動態，從而導致對 3PL 儲存和分銷服務的採用增加。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章美國醫藥第三方物流(3PL) 服務市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/輔助市場展望。
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 市場分析工具
    • 波特五力分析
    • PESTEL 分析
    • COVID-19影響分析

第 4 章美國醫藥第三方物流(3PL) 服務市場：產品類型估計與趨勢分析

  • 細分儀表板
  • 美國醫藥第三方物流(3PL) 服務市場：產品類型變化分析
  • 2018 - 2030 年美國醫藥第三方物流(3PL) 服務規模及趨勢分析（依產品類型）
  • 品牌
  • 非專利的
  • 生物相似藥
  • 疫苗
  • 細胞療法
  • 基因治療
  • 其他

第5章美國醫藥第三方物流（3PL）服務市場：溫度估計與趨勢分析

  • 細分儀表板
  • 美國醫藥第三者物流(3PL) 服務市場：溫度波動分析
  • 2018 年至 2030 年美國醫藥第三人物流(3PL) 服務規模及溫度趨勢分析
  • 環境的
  • 冷藏
  • 冷凍
  • 超冷凍/冷凍
  • 低溫

第6章美國醫藥第三方物流(3PL) 服務市場：治療領域估計與趨勢分析

  • 細分儀表板
  • 美國醫藥第三方物流(3PL) 服務市場：治療領域變化分析
  • 2018 年至 2030 年美國醫藥第三方物流(3PL) 服務規模及趨勢分析（依治療領域）
  • 腫瘤學
  • 心血管疾病
  • 感染疾病
  • 神經病學
  • 糖尿病
  • 腎臟科
  • 風濕病學
  • 過敏/氣喘
  • 胃腸病學
  • 眼科
  • 其他

第 7 章：美國醫藥第三方物流(3PL) 服務市場：製造商規模估計與趨勢分析

  • 細分儀表板
  • 美國醫藥第三方物流(3PL) 服務市場：製造商規模變化分析
  • 2018 年至 2030 年美國醫藥第三方物流(3PL) 服務規模及趨勢分析（依製造商規模）
  • 大的
  • 中等的
  • 小的

第 8 章：美國醫藥第三方物流(3PL) 服務市場：服務評估與趨勢分析

  • 細分儀表板
  • 美國醫藥第三方物流（3PL）服務市場：服務變化分析
  • 2018 年至 2030 年美國醫藥第三方物流(3PL) 服務規模與趨勢分析（依服務分類）
  • 儲存和運輸
  • 訂單到現金
  • 標題 型號
  • DSCSA 和序列化服務
  • 藥品樣品
  • 其他

第9章 競爭格局

  • 公司分類
  • 2024 年企業市場分析
  • 公司簡介
    • CEVA Logistics
    • Cencora Corporation（ICS）
    • DB SCHENKER
    • Kuehne+Nagel
    • Kerry Logistics Network Limited
    • Cardinal Health
    • McKesson Corporation
    • EVERSANA.
    • Thermo Fisher Scientific Inc.
    • Knipper Health
Product Code: GVR-4-68040-499-2

U.S. Pharmaceutical Third-party Logistics Services Market Growth & Trends:

The U.S. pharmaceutical third-party logistics services market size is expected to reach USD 75.41 billion by 2030 and it is anticipated to grow at a CAGR of 8.90% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven due to the growing demand for efficient and secure supply chain solutions, increasing complexity in pharmaceutical distribution, and the need for compliance with stringent regulatory standards. Moreover, the rise in demand for temperature-sensitive and specialty drugs, such as biologics and vaccines, has heightened the importance of cold chain logistics, prompting pharmaceutical companies to rely on 3PL providers for advanced storage and transportation solutions.

Furthermore, is the development of advanced technologies to improve the efficiency and security of drug distribution is also contributing to the market growth. As pharmaceutical logistics operations become more complex, there is a growing reliance on automated data reporting systems to streamline compliance and performance monitoring. Automated reporting solutions help pharmaceutical 3PL providers generate real-time, accurate reports on key performance indicators (KPIs) such as on-time delivery rates, product condition, and regulatory compliance. These systems also automate the generation of reports required by regulatory bodies, reducing manual effort and ensuring that all necessary documentation is submitted on time.

In addition, the growing demand for temperature-sensitive pharmaceuticals and biopharmaceuticals is significantly fueling the expansion of the cold chain logistics market. Growing demand for the safe storage and transportation of these delicate products has led the companies to innovative cold chain solutions that safeguard product quality and efficacy. Moreover, increasing technological advancements by integrating artificial intelligence is further boosting the demand for cold chain logistics in the pharmaceutical sector. According to an article published by Pharmaceutical Commerce in October 2024, artificial intelligence (AI) has the potential to revolutionize the logistics of temperature-sensitive pharmaceuticals shipped through the cold chain in several transformative ways. AI can enhance the supply chain's efficiency and reliability through predictive analytics, real-time monitoring, and optimization of routes and resources.

Some of the key players in the market are Cencora Corporation, Kuehne+Nagel, Kerry Logistics Network Limited, Cardinal Health, McKesson Corporation, Thermo Fisher Scientific, among others. Market players are adopting key strategic initiatives to boost their market presence and expand their business. For instance, in April 2023, Kuehne+Nagel announced a 400,000 sq. ft. contract logistics fulfillment center near Dallas/Fort Worth International Airport. Positioned three miles from the terminals, the facility highlighted the company's strategic investment in healthcare logistics, designed to serve multiple clients with state-of-the-art capabilities.

U.S. Pharmaceutical Third-party Logistics Services Market Report Highlights:

  • Based on product, the branded drugs segment dominated the market in 2024 due to growing incidence of chronic diseases such as diabetes, hypertension, and cardiovascular conditions. The increasing cases of these condition have led to the rising demand for branded drugs in the U.S.
  • Based on the temperature, ambient held the largest revenue share in 2024. Ambient storage is essential for products that do not require refrigeration or freezing, such as certain oral medications, over-the-counter drugs, among others.
  • Based on the therapeutic area, oncology held the largest revenue share in 2024. The market for the segment is likely to expand with an increasing number of cancer cases across the country. Furthermore, recent trends have shown a shifting focus towards pharmaceutical products with significant advancements made in the treatment of cancer.
  • Based on the manufacturer size, large held the largest revenue share in 2024. The large manufacturers have extensive resources and established supply chains. These companies typically have significant production capacities and a broad portfolio of products, which allows them to negotiate favorable terms with logistics providers.
  • Based on the service, storage and shipping held the largest revenue share in 2024. With the increasingly competitive business landscape and complex process, several pharmaceutical companies are constantly seeking new ways to optimize their supply chain productivity and ensure compliance with industry regulations, further adopting the 3PL storage and shipping services.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. The Rise of E-Commerce
      • 3.2.1.2. Growing Demand for Outsourcing Services
      • 3.2.1.3. Rising Demand for Cold Chain Logistics
      • 3.2.1.4. Growing Applications of Reverse Logistics in Biopharmaceutical Industry
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Operational Costs
      • 3.2.2.2. Compliance Issues While Outsourcing
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Product Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Product Type Movement Analysis
  • 4.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Generic
    • 4.5.1. Generic market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Biosimilar
    • 4.6.1. Biosimilar market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Vaccine
    • 4.7.1. Vaccine market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Cell Therapy
    • 4.8.1. Cell therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Gene Therapy
    • 4.9.1. Gene therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Temperature Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Temperature Movement Analysis
  • 5.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Temperature, 2018 to 2030 (USD Million)
  • 5.4. Ambient
    • 5.4.1. Ambient market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Refrigerated
    • 5.5.1. Refrigerated market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Frozen
    • 5.6.1. Frozen market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Ultra-frozen/Deep-Frozen
    • 5.7.1. Ultra-frozen/Deep-Frozen market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Cryogenic
    • 5.8.1. Cryogenic market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Therapeutic Area Movement Analysis
  • 6.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Cardiovascular Diseases
    • 6.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Infectious Diseases
    • 6.6.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Neurology
    • 6.7.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Nephrology
    • 6.9.1. Nephrology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. Rheumatology
    • 6.10.1. Rheumatology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.11. Allergy/Asthma
    • 6.11.1. Allergy/Asthma market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.12. Gastroenterology
    • 6.12.1. Gastroenterology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.13. Ophthalmology
    • 6.13.1. Ophthalmology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.14. Others
    • 6.14.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Manufacturer Size Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Manufacturer Size Movement Analysis
  • 7.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Manufacturer Size, 2018 to 2030 (USD Million)
  • 7.4. Large
    • 7.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Medium
    • 7.5.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Small
    • 7.6.1. Small market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Service Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Service Movement Analysis
  • 8.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 8.4. Storage and Shipping
    • 8.4.1. Storage and Shipping market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Order-to-cash
    • 8.5.1. Order-to-cash market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Title Model
    • 8.6.1. Title Model market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. DSCSA and Serialization Services
    • 8.7.1. DSCSA and Serialization Services market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Pharmaceutical Sampling
    • 8.8.1. Pharmaceutical Sampling market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. Others
    • 8.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Position Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. CEVA Logistics
      • 9.3.1.1. Company overview
      • 9.3.1.2. Financial performance
      • 9.3.1.3. Service benchmarking
      • 9.3.1.4. Strategic initiatives
    • 9.3.2. Cencora Corporation (ICS)
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Service benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. DB SCHENKER
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Service benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Kuehne+Nagel
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Service benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Kerry Logistics Network Limited
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Service benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Cardinal Health
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Service benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. McKesson Corporation
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Service benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. EVERSANA.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Service benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Thermo Fisher Scientific Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Service benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Knipper Health
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Service benchmarking
      • 9.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Product Type, 2018 - 2030 (USD Million)
  • Table 4 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Temperature, 2018 - 2030 (USD Million)
  • Table 5 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 6 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Manufacturer Size, 2018 - 2030 (USD Million)
  • Table 7 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Service, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Pharmaceutical Third-Party Logistics (3PL) Services, Market Segmentation
  • Fig. 7 Market Driver Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Branded, 2018 - 2030 (USD Million)
  • Fig. 12 U.S Pharmaceutical Third-Party Logistics (3PL) Services, for Generic, 2018 - 2030 (USD Million)
  • Fig. 13 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Biosimilar, 2018 - 2030 (USD Million)
  • Fig. 14 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Vaccine, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Cell Therapy, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Gene Therapy, 2018 - 2030 (USD Million)
  • Fig. 17 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Ambient, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Refrigerated, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Frozen, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Ultra-frozen/Deep-Frozen, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Cryogenic, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Oncology, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for cardiovascular diseases, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Neurology, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Diabetes, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Nephrology, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Rheumatology, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Allergy/Asthma, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Gastroenterology, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Ophthalmology, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Large, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Medium, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Small, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Storage and Shipping, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Order-to-cash, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Title Model, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for DSCSA and Serialization Services, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Pharmaceutical Sampling, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Others, 2018 - 2030 (USD Million)